PT89279B - Processo para a preparacao de uma nova forma cristalina de ciclosporinas e de composicoes farmaceuticas que as contem - Google Patents

Processo para a preparacao de uma nova forma cristalina de ciclosporinas e de composicoes farmaceuticas que as contem Download PDF

Info

Publication number: PT89279B
Authority: PT; Portugal
Prior art keywords: ciclosporin; approximately; cyclosporine; orthorhombic; treatment
Prior art date: 1987-12-21

Application number

PT8927988A

Other languages

English (en)

Portuguese (pt)

Other versions

PT89279A (pt

Inventor

Friedrich Richter

Danielle Giron

Martin List

Yasuyukl Uike

Hans Peter Weber

Original Assignee

Sandoz Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-12-21

Filing date

1988-12-20

Publication date

1993-08-31

1988-12-20 Application filed by Sandoz Sa filed Critical Sandoz Sa

1989-12-29 Publication of PT89279A publication Critical patent/PT89279A/pt

1993-08-31 Publication of PT89279B publication Critical patent/PT89279B/pt

Links

229930182912 cyclosporin Natural products 0.000 title claims description 63
238000000034 method Methods 0.000 title claims description 56
239000008194 pharmaceutical composition Substances 0.000 title claims description 8
108010036941 Cyclosporins Proteins 0.000 title description 3
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 109
108010036949 Cyclosporine Proteins 0.000 claims description 102
229960001265 ciclosporin Drugs 0.000 claims description 101
238000011282 treatment Methods 0.000 claims description 70
238000002360 preparation method Methods 0.000 claims description 33
230000008569 process Effects 0.000 claims description 33
229920001223 polyethylene glycol Polymers 0.000 claims description 25
239000002202 Polyethylene glycol Substances 0.000 claims description 17
239000003795 chemical substances by application Substances 0.000 claims description 14
239000002904 solvent Substances 0.000 claims description 9
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
239000004480 active ingredient Substances 0.000 claims description 5
230000015572 biosynthetic process Effects 0.000 claims description 5
239000003085 diluting agent Substances 0.000 claims description 5
229930105110 Cyclosporin A Natural products 0.000 claims description 3
230000003110 anti-inflammatory effect Effects 0.000 claims description 2
230000001506 immunosuppresive effect Effects 0.000 claims description 2
229920001451 polypropylene glycol Polymers 0.000 claims description 2
239000012467 final product Substances 0.000 claims 2
239000003937 drug carrier Substances 0.000 claims 1
239000000203 mixture Substances 0.000 description 93
239000002245 particle Substances 0.000 description 49
239000000047 product Substances 0.000 description 31
230000000699 topical effect Effects 0.000 description 31
201000004681 Psoriasis Diseases 0.000 description 27
239000007924 injection Substances 0.000 description 27
238000002347 injection Methods 0.000 description 27
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 26
201000010099 disease Diseases 0.000 description 24
-1 for example Chemical class 0.000 description 23
239000000499 gel Substances 0.000 description 19
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
239000013078 crystal Substances 0.000 description 18
230000003902 lesion Effects 0.000 description 18
229940068196 placebo Drugs 0.000 description 18
239000000902 placebo Substances 0.000 description 18
239000000243 solution Substances 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
238000012360 testing method Methods 0.000 description 14
229920003171 Poly (ethylene oxide) Polymers 0.000 description 13
230000000694 effects Effects 0.000 description 11
229920000159 gelatin Polymers 0.000 description 11
235000019322 gelatine Nutrition 0.000 description 11
239000007788 liquid Substances 0.000 description 11
238000012986 modification Methods 0.000 description 11
230000004048 modification Effects 0.000 description 11
238000005809 transesterification reaction Methods 0.000 description 10
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 9
206010015150 Erythema Diseases 0.000 description 9
239000006071 cream Substances 0.000 description 9
238000002425 crystallisation Methods 0.000 description 9
230000008025 crystallization Effects 0.000 description 9
231100000321 erythema Toxicity 0.000 description 9
238000009472 formulation Methods 0.000 description 9
239000004615 ingredient Substances 0.000 description 9
239000004094 surface-active agent Substances 0.000 description 9
108010010803 Gelatin Proteins 0.000 description 8
239000002253 acid Substances 0.000 description 8
230000036576 dermal application Effects 0.000 description 8
239000003814 drug Substances 0.000 description 8
235000011852 gelatine desserts Nutrition 0.000 description 8
239000013081 microcrystal Substances 0.000 description 8
230000009467 reduction Effects 0.000 description 8
239000000725 suspension Substances 0.000 description 8
238000002560 therapeutic procedure Methods 0.000 description 8
201000004624 Dermatitis Diseases 0.000 description 7
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
239000013543 active substance Substances 0.000 description 7
239000002775 capsule Substances 0.000 description 7
239000002552 dosage form Substances 0.000 description 7
229940079593 drug Drugs 0.000 description 7
239000010419 fine particle Substances 0.000 description 7
230000006872 improvement Effects 0.000 description 7
229910052740 iodine Inorganic materials 0.000 description 7
230000008018 melting Effects 0.000 description 7
238000002844 melting Methods 0.000 description 7
239000003921 oil Substances 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
206010046851 Uveitis Diseases 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
239000006185 dispersion Substances 0.000 description 6
238000009826 distribution Methods 0.000 description 6
239000000463 material Substances 0.000 description 6
235000019198 oils Nutrition 0.000 description 6
239000002674 ointment Substances 0.000 description 6
239000008389 polyethoxylated castor oil Substances 0.000 description 6
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 6
238000007127 saponification reaction Methods 0.000 description 6
239000000126 substance Substances 0.000 description 6
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
206010003645 Atopy Diseases 0.000 description 5
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
208000003251 Pruritus Diseases 0.000 description 5
238000013019 agitation Methods 0.000 description 5
239000004599 antimicrobial Substances 0.000 description 5
206010003246 arthritis Diseases 0.000 description 5
235000014113 dietary fatty acids Nutrition 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
150000002170 ethers Chemical class 0.000 description 5
239000000194 fatty acid Substances 0.000 description 5
229930195729 fatty acid Natural products 0.000 description 5
239000008394 flocculating agent Substances 0.000 description 5
238000000227 grinding Methods 0.000 description 5
239000011630 iodine Substances 0.000 description 5
239000003381 stabilizer Substances 0.000 description 5
238000003756 stirring Methods 0.000 description 5
OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
206010010741 Conjunctivitis Diseases 0.000 description 4
206010048768 Dermatosis Diseases 0.000 description 4
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 4
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
206010061218 Inflammation Diseases 0.000 description 4
208000027418 Wounds and injury Diseases 0.000 description 4
230000001363 autoimmune Effects 0.000 description 4
239000004359 castor oil Substances 0.000 description 4
235000019438 castor oil Nutrition 0.000 description 4
230000003111 delayed effect Effects 0.000 description 4
238000004090 dissolution Methods 0.000 description 4
230000002500 effect on skin Effects 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
239000008187 granular material Substances 0.000 description 4
238000000265 homogenisation Methods 0.000 description 4
230000004054 inflammatory process Effects 0.000 description 4
208000014674 injury Diseases 0.000 description 4
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
230000006911 nucleation Effects 0.000 description 4
238000010899 nucleation Methods 0.000 description 4
239000004006 olive oil Substances 0.000 description 4
235000008390 olive oil Nutrition 0.000 description 4
229940068886 polyethylene glycol 300 Drugs 0.000 description 4
229920000056 polyoxyethylene ether Polymers 0.000 description 4
229920000136 polysorbate Polymers 0.000 description 4
239000000843 powder Substances 0.000 description 4
206010039073 rheumatoid arthritis Diseases 0.000 description 4
208000017520 skin disease Diseases 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000012453 solvate Substances 0.000 description 4
235000015112 vegetable and seed oil Nutrition 0.000 description 4
239000008158 vegetable oil Substances 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
201000004384 Alopecia Diseases 0.000 description 3
208000023275 Autoimmune disease Diseases 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
206010012438 Dermatitis atopic Diseases 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
235000019483 Peanut oil Nutrition 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
231100000360 alopecia Toxicity 0.000 description 3
201000008937 atopic dermatitis Diseases 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
239000011248 coating agent Substances 0.000 description 3
238000000576 coating method Methods 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
RKTYLMNFRDHKIL-UHFFFAOYSA-N copper;5,10,15,20-tetraphenylporphyrin-22,24-diide Chemical compound [Cu+2].C1=CC(C(=C2C=CC([N-]2)=C(C=2C=CC=CC=2)C=2C=CC(N=2)=C(C=2C=CC=CC=2)C2=CC=C3[N-]2)C=2C=CC=CC=2)=NC1=C3C1=CC=CC=C1 RKTYLMNFRDHKIL-UHFFFAOYSA-N 0.000 description 3
230000006378 damage Effects 0.000 description 3
230000008030 elimination Effects 0.000 description 3
238000003379 elimination reaction Methods 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
239000003925 fat Substances 0.000 description 3
235000019197 fats Nutrition 0.000 description 3
150000002334 glycols Chemical class 0.000 description 3
238000001802 infusion Methods 0.000 description 3
230000007803 itching Effects 0.000 description 3
206010023332 keratitis Diseases 0.000 description 3
201000010666 keratoconjunctivitis Diseases 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
239000000312 peanut oil Substances 0.000 description 3
235000019271 petrolatum Nutrition 0.000 description 3
229920005862 polyol Polymers 0.000 description 3
150000003077 polyols Chemical class 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
229920000053 polysorbate 80 Polymers 0.000 description 3
230000002265 prevention Effects 0.000 description 3
230000002035 prolonged effect Effects 0.000 description 3
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
229960003415 propylparaben Drugs 0.000 description 3
230000001185 psoriatic effect Effects 0.000 description 3
239000011734 sodium Substances 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
239000003826 tablet Substances 0.000 description 3
150000003626 triacylglycerols Chemical class 0.000 description 3
238000002604 ultrasonography Methods 0.000 description 3
239000003871 white petrolatum Substances 0.000 description 3
KFTBCJUZVUOWRL-UHFFFAOYSA-N 1-fluoro-2,3-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(F)=C1[N+]([O-])=O KFTBCJUZVUOWRL-UHFFFAOYSA-N 0.000 description 2
RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 2
LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 2
208000002691 Choroiditis Diseases 0.000 description 2
206010012442 Dermatitis contact Diseases 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
239000001828 Gelatine Substances 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
240000007049 Juglans regia Species 0.000 description 2
235000009496 Juglans regia Nutrition 0.000 description 2
206010024438 Lichenification Diseases 0.000 description 2
235000019482 Palm oil Nutrition 0.000 description 2
239000004264 Petrolatum Substances 0.000 description 2
208000003971 Posterior uveitis Diseases 0.000 description 2
208000025747 Rheumatic disease Diseases 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
206010040844 Skin exfoliation Diseases 0.000 description 2
229920002125 Sokalan® Polymers 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
230000009471 action Effects 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
239000008168 almond oil Substances 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
208000037849 arterial hypertension Diseases 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
208000010247 contact dermatitis Diseases 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000002285 corn oil Substances 0.000 description 2
235000005687 corn oil Nutrition 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
238000010586 diagram Methods 0.000 description 2
230000002996 emotional effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000003889 eye drop Substances 0.000 description 2
230000001815 facial effect Effects 0.000 description 2
150000002191 fatty alcohols Chemical class 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
125000005456 glyceride group Chemical group 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
239000012051 hydrophobic carrier Substances 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
230000009610 hypersensitivity Effects 0.000 description 2
239000003018 immunosuppressive agent Substances 0.000 description 2
230000036512 infertility Effects 0.000 description 2
230000004968 inflammatory condition Effects 0.000 description 2
229940057995 liquid paraffin Drugs 0.000 description 2
238000005259 measurement Methods 0.000 description 2
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
229960002216 methylparaben Drugs 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
239000002540 palm oil Substances 0.000 description 2
229940066842 petrolatum Drugs 0.000 description 2
230000019612 pigmentation Effects 0.000 description 2
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
229940068968 polysorbate 80 Drugs 0.000 description 2
229940068965 polysorbates Drugs 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
239000012049 topical pharmaceutical composition Substances 0.000 description 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
235000020234 walnut Nutrition 0.000 description 2
238000005406 washing Methods 0.000 description 2
HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical class CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical class CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 1
OFQCQIGMURIECL-UHFFFAOYSA-N 2-[2-(diethylamino)ethyl]-2',6'-dimethylspiro[isoquinoline-4,4'-oxane]-1,3-dione;phosphoric acid Chemical compound OP(O)(O)=O.O=C1N(CCN(CC)CC)C(=O)C2=CC=CC=C2C21CC(C)OC(C)C2 OFQCQIGMURIECL-UHFFFAOYSA-N 0.000 description 1
JKXYOQDLERSFPT-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO JKXYOQDLERSFPT-UHFFFAOYSA-N 0.000 description 1
MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
244000144725 Amygdalus communis Species 0.000 description 1
235000011437 Amygdalus communis Nutrition 0.000 description 1
241001550224 Apha Species 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000023328 Basedow disease Diseases 0.000 description 1
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
206010007764 Cataract subcapsular Diseases 0.000 description 1
241000700198 Cavia Species 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
244000060011 Cocos nucifera Species 0.000 description 1
235000013162 Cocos nucifera Nutrition 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
206010011715 Cyclitis Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
208000035874 Excoriation Diseases 0.000 description 1
206010018364 Glomerulonephritis Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
208000023661 Haematological disease Diseases 0.000 description 1
206010019755 Hepatitis chronic active Diseases 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
206010020649 Hyperkeratosis Diseases 0.000 description 1
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
208000029523 Interstitial Lung disease Diseases 0.000 description 1
201000002287 Keratoconus Diseases 0.000 description 1
208000001126 Keratosis Diseases 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
206010068773 Mechanical urticaria Diseases 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
206010033546 Pallor Diseases 0.000 description 1
101150034459 Parpbp gene Proteins 0.000 description 1
241000287107 Passer Species 0.000 description 1
241000721454 Pemphigus Species 0.000 description 1
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
101150086986 Pigu gene Proteins 0.000 description 1
241000101040 Pityriasis Species 0.000 description 1
206010065159 Polychondritis Diseases 0.000 description 1
108010002885 Polygeline Proteins 0.000 description 1
229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
229920001219 Polysorbate 40 Polymers 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
208000012654 Primary biliary cholangitis Diseases 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
206010053262 Skin swelling Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920001304 Solutol HS 15 Polymers 0.000 description 1
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
235000019498 Walnut oil Nutrition 0.000 description 1
208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000001785 acacia senegal l. willd gum Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
208000002205 allergic conjunctivitis Diseases 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
230000009285 allergic inflammation Effects 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
230000000118 anti-neoplastic effect Effects 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000003096 antiparasitic agent Substances 0.000 description 1
229940125687 antiparasitic agent Drugs 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
239000000305 astragalus gummifer gum Substances 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
238000004061 bleaching Methods 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229940074979 cetyl palmitate Drugs 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
208000007287 cheilitis Diseases 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
238000011970 concomitant therapy Methods 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
238000012864 cross contamination Methods 0.000 description 1
238000002447 crystallographic data Methods 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
201000000409 dermatographia Diseases 0.000 description 1
230000035618 desquamation Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
230000003205 diastolic effect Effects 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004821 distillation Methods 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000035622 drinking Effects 0.000 description 1
239000006196 drop Substances 0.000 description 1
210000003027 ear inner Anatomy 0.000 description 1
229960001484 edetic acid Drugs 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
208000027993 eye symptom Diseases 0.000 description 1
210000000744 eyelid Anatomy 0.000 description 1
210000000887 face Anatomy 0.000 description 1
208000020157 familial dermatographia Diseases 0.000 description 1
150000002194 fatty esters Chemical class 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
230000008570 general process Effects 0.000 description 1
125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
230000003779 hair growth Effects 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
239000012052 hydrophilic carrier Substances 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
206010021198 ichthyosis Diseases 0.000 description 1
208000016036 idiopathic nephrotic syndrome Diseases 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
238000002650 immunosuppressive therapy Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
239000002563 ionic surfactant Substances 0.000 description 1
229960004125 ketoconazole Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
230000006651 lactation Effects 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
229910052919 magnesium silicate Inorganic materials 0.000 description 1
235000019792 magnesium silicate Nutrition 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
238000003801 milling Methods 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
230000003589 nefrotoxic effect Effects 0.000 description 1
231100000381 nephrotoxic Toxicity 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
210000002445 nipple Anatomy 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229940127234 oral contraceptive Drugs 0.000 description 1
239000003539 oral contraceptive agent Substances 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
238000002103 osmometry Methods 0.000 description 1
229940046781 other immunosuppressants in atc Drugs 0.000 description 1
QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
244000045947 parasite Species 0.000 description 1
238000010951 particle size reduction Methods 0.000 description 1
239000006072 paste Substances 0.000 description 1
235000011837 pasties Nutrition 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000003209 petroleum derivative Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
229960002695 phenobarbital Drugs 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
229960002036 phenytoin Drugs 0.000 description 1
239000003058 plasma substitute Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
229920001281 polyalkylene Polymers 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
229950008882 polysorbate Drugs 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
235000015277 pork Nutrition 0.000 description 1
238000000634 powder X-ray diffraction Methods 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
238000009597 pregnancy test Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
230000004044 response Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
201000008261 skin carcinoma Diseases 0.000 description 1
206010040872 skin infection Diseases 0.000 description 1
206010040882 skin lesion Diseases 0.000 description 1
231100000444 skin lesion Toxicity 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 1
229940084026 sodium valproate Drugs 0.000 description 1
239000002594 sorbent Substances 0.000 description 1
235000011076 sorbitan monostearate Nutrition 0.000 description 1
239000001587 sorbitan monostearate Substances 0.000 description 1
229940035048 sorbitan monostearate Drugs 0.000 description 1
238000005507 spraying Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000035900 sweating Effects 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
238000009210 therapy by ultrasound Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
229940100613 topical solution Drugs 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
208000018464 vernal keratoconjunctivitis Diseases 0.000 description 1
239000008170 walnut oil Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
210000002268 wool Anatomy 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

PT8927988A 1987-12-21 1988-12-20 Processo para a preparacao de uma nova forma cristalina de ciclosporinas e de composicoes farmaceuticas que as contem PT89279B (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US13623087A	1987-12-21	1987-12-21

Publications (2)

Publication Number	Publication Date
PT89279A PT89279A (pt)	1989-12-29
PT89279B true PT89279B (pt)	1993-08-31

Family

ID=22471933

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT8927988A PT89279B (pt)	1987-12-21	1988-12-20	Processo para a preparacao de uma nova forma cristalina de ciclosporinas e de composicoes farmaceuticas que as contem

Country Status (8)

Country	Link
CZ (1)	CZ279654B6 (de)
DD (1)	DD283404A5 (de)
PL (1)	PL155712B1 (de)
PT (1)	PT89279B (de)
RU (1)	RU2002754C1 (de)
SK (1)	SK278320B6 (de)
UA (1)	UA11244A1 (de)
ZA (1)	ZA889540B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9208712D0 (en) *	1992-04-22	1992-06-10	Sandoz Ltd	Pharmaceutical compositions containing cyclosporin derivates
DE19613933A1 (de) *	1996-04-06	1997-10-09	Merck Patent Gmbh	Cyclische Adhäsionsinhibitoren
SE9604341D0 (sv) *	1996-11-26	1996-11-26	Ferring Bv	Hepta-peptide oxytocin analogue

1988
- 1988-12-20 PL PL27656588A patent/PL155712B1/pl unknown
- 1988-12-20 PT PT8927988A patent/PT89279B/pt not_active IP Right Cessation
- 1988-12-20 SK SK8474-88A patent/SK278320B6/sk unknown
- 1988-12-20 DD DD32344488A patent/DD283404A5/de not_active IP Right Cessation
- 1988-12-20 CZ CS888474A patent/CZ279654B6/cs not_active IP Right Cessation
- 1988-12-21 RU SU4613289 patent/RU2002754C1/ru active
- 1988-12-21 UA UA4613289A patent/UA11244A1/uk unknown
- 1988-12-21 ZA ZA889540A patent/ZA889540B/xx unknown

Also Published As

Publication number	Publication date
CZ847488A3 (en)	1995-02-15
PL155712B1 (en)	1991-12-31
RU2002754C1 (ru)	1993-11-15
PL276565A1 (en)	1989-08-21
UA11244A1 (uk)	1996-12-25
SK847488A3 (en)	1996-10-02
PT89279A (pt)	1989-12-29
DD283404A5 (de)	1990-10-10
CZ279654B6 (cs)	1995-05-17
SK278320B6 (en)	1996-10-02
ZA889540B (en)	1990-08-29

Legal Events

Date

Code

Title

Description

1993-08-31

FG3A

Patent granted, date of granting

Effective date: 19930203

1998-01-30

PC3A

Transfer or assignment

Free format text: 971017 NOVARTIS AG CH

2009-01-07

MM4A

Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20081220

Publication	Publication Date	Title
AU626274B2 (en)	1992-07-30	New ciclosporin crystal form, processes for its production, pharmaceutical compositions containing it and its use.
RU2646802C2 (ru)	2018-03-07	Растворы на основе мелатонина и порошки для их получения
ES2226976T3 (es)	2005-04-01	Formulaciones galenicas de fenofibrato y su procedimiento de obtencion.
ES2467676T3 (es)	2014-06-12	Polvo de un compuesto orgánico combinado para uso médico, método para producir el mismo y suspensión del mismo
JPH09328427A (ja)	1997-12-22	新規なフェノフィブラート含有製薬用組成物及びそれらの用途
JPH02121929A (ja)	1990-05-09	シクロスポリン含有医薬組成物
CN100518726C (zh)	2009-07-29	莫达非尼化合物的药用溶液
WO1999049845A1 (de)	1999-10-07	Perorale wirkstoff-suspension
WO2004096261A1 (es)	2004-11-11	Metodo para preparar una solucion acuosa de ciclosporina-a y solucion acuosa resultante
CZ306618B6 (cs)	2017-04-05	Kompozice obsahující sloučeniny modafinylu
ES2235765T3 (es)	2005-07-16	Composiciones farmaceuticas que comprenden ciclosporina como ingredientes activos.
EP4203919B1 (de)	2024-01-31	Lipidbasierte zusammensetzung zur oralen verabreichung von bradykinin-b2-rezeptor-antagonisten
SK847488A3 (en)	1996-10-02	Process for producing of cyclosporine a
JPWO2016039422A1 (ja)	2017-06-22	点眼用懸濁製剤
BR102024008610A2 (pt)	2025-11-04	Composição em pó para solução nasal, kit para lavagem nasal compreendendo furoato de mometasona e cloreto de sódio, uso terapêutico dos mesmos e processo para preparar dita composição
HK40088043A (en)	2023-09-22	Lipid-based composition for oral administration of bradykinin b2-receptor antagonists
WO2023193074A1 (pt)	2023-10-12	Uso de prednisolona ou seus sais farmacêuticos ativos em uma composição farmacêutica, composição farmacêutica, seu processo de preparação e seu uso
KR20250048301A (ko)	2025-04-08	아비라테론 아세테이트의 경구 제형 및 이의 제조방법
AU2002211677B2 (en)	2006-03-23	Compositions comprising modafinil compounds
AU2002211677A1 (en)	2002-06-27	Compositions comprising modafinil compounds
UA75094C2 (uk)	2006-03-15	Фармацевтична композиція, що містить сполуку модафінілу, та спосіб лікування